We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+3.9%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.35B
AUM Growth
-$238M
Cap. Flow
-$201M
Cap. Flow %
-14.89%
Top 10 Hldgs %
64.03%
Holding
94
New
18
Increased
13
Reduced
24
Closed
26

Top Buys

Rank Stock Value
1
INZY
Inozyme Pharma
INZY
+$50.4M
2
CMPI
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
+$46.2M
3
AMGN icon
Amgen
AMGN
+$27.7M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$19.8M
5
NCNA
NuCana
NCNA
+$18.1M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$84.7M
2
GILD icon
Gilead Sciences
GILD
+$31M
3
CHRS icon
Coherus Oncology
CHRS
+$27.9M
4
AMRN
Amarin Corp
AMRN
+$24.2M
5
MRK icon
Merck
MRK
+$21.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$224M 16.61%
3,100,560
– –
ASND icon
2
Ascendis Pharma A/S
ASND
$16.7B
$171M 12.7%
1,109,874
– –
KRTX
3
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$151M 11.19%
1,952,441
+66,839
+4% +$5.7M
YMAB
4
DELISTED
Y-mAbs Therapeutics
YMAB
$84.2M 6.25%
2,194,278
– –
INZY
5
DELISTED
Inozyme Pharma
INZY
$53.3M 3.95%
+2,028,308
New +$50.4M
CMPI
6
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$41.5M 3.08%
+3,606,707
New +$46.2M
AMGN icon
7
CALL
Amgen
AMGN
$203B
$41.2M 3.06%
+59,500
New +$14.7M
AKUS
8
DELISTED
Akouos Inc
AKUS
$34.6M 2.57%
1,515,073
– –
UTHR icon
9
United Therapeutics
UTHR
$26.3B
$32.4M 2.4%
320,959
+16,397
+5% +$1.8M
ABBV icon
10
AbbVie
ABBV
$458B
$29.9M 2.22%
341,340
+89,381
+35% +$8.41M
NCNA
11
NuCana
NCNA
$5.37M
$29M 2.15%
1,120
+667
+147% +$18.1M
AMGN icon
12
Amgen
AMGN
$203B
$28.4M 2.1%
+111,619
New +$27.7M
GRTX
13
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$27.9M 2.07%
3,083,712
– –
NXTC icon
14
NextCure
NXTC
$17.3M
$23.5M 1.74%
222,655
– –
LLY icon
15
Eli Lilly
LLY
$1.07T
$21.1M 1.56%
142,432
-6,468
-4% -$1M
INSM icon
16
Insmed
INSM
$23.2B
$19.8M 1.47%
615,143
+131,176
+27% +$3.77M
BMRN icon
17
BioMarin Pharmaceuticals
BMRN
$11.5B
$19.7M 1.46%
258,653
+195,756
+311% +$19.8M
PTCT icon
18
PTC Therapeutics
PTCT
$6.37B
$18.9M 1.4%
405,152
-33,118
-8% -$1.63M
JAZZ icon
19
Jazz Pharmaceuticals
JAZZ
$15.9B
$18.6M 1.38%
130,268
-113,085
-46% -$14M
MRK icon
20
Merck
MRK
$324B
$15.8M 1.17%
199,706
-273,129
-58% -$21.4M
MRUS
21
DELISTED
Merus
MRUS
$15.7M 1.17%
1,311,039
– –
ITCI
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$12.9M 0.96%
503,555
+261,647
+108% +$5.97M
OBSV
23
DELISTED
ObsEva SA Ordinary Shares
OBSV
$11.8M 0.87%
4,749,623
– –
LONA
24
LeonaBio Inc
LONA
$69.4M
$9.4M 0.7%
+50,917
New +$8.5M
MRNS
25
CALL
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$8.99M 0.67%
+175,000
New +$1.51M
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2020 Portfolio in Review

As of Q3 2020, Sofinnova Investments held 94 positions worth $1.35B, down 15% from $1.59B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Sofinnova Investments withdrew a net $201M in Q3 2020, closing 26 positions and reducing 24 holdings. Its most notable exit was Principia Biopharma Inc. Common Stock, an estimated $84.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Inozyme Pharma worth $53.3M.

  • Sofinnova Investments's largest Q3 2020 buy was Inozyme Pharma: 2,028,308 shares worth $53.3M.
  • Sofinnova Investments added most to BioMarin Pharmaceuticals in Q3 2020, an estimated $19.8M increase.
  • Sofinnova Investments's biggest Q3 2020 reduction was Coherus Oncology, cutting an estimated $27.9M.
  • Sofinnova Investments fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $84.7M.
  • Sofinnova Investments's ten largest holdings make up 64% of its $1.35B portfolio in Q3 2020.
  • Sofinnova Investments opened 18 new positions and closed 26 in Q3 2020.
  • Sofinnova Investments's portfolio value fell 15% quarter-over-quarter to $1.35B.

Based on Sofinnova Investments's 13F filing for Q3 2020, filed 13 Nov 2020.